Merrill keeps UCB at buy

UCB was retained at buy by Merrill Lynch analyst Erica Whittaker. Cimzia is UCB's key growth driver and the analyst forecasts 2010 Cimzia sales of $670 million in Crohn's and $270 million in rheumatoid arthritis. The clinical data from Abbott's Humira study are similar to those seen for Remicade and Cimzia (PRECiSE 2 study), in which about 40% of Crohn's patients achieved disease remission after 6 months. Merrill expects the market entry of Cimzia and Humira to expand the global Crohn's biologics market to $2 billion in 2010, with all three drugs capturing a third of the Crohn's biologics market. Shares of the Brussels, Belgium, biopharmaceutical company were down €0.47 or 0.27%, at €40.99 on volume of 564,985 shares versus the three-month running average of 371,329 shares. (Brussels: UCB)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.